vs
DOMO, INC.（DOMO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是DOMO, INC.的1.6倍（$127.1M vs $79.4M），再鼎医药同比增速更快（17.1% vs -0.5%），DOMO, INC.自由现金流更多（$1.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -0.5%）
Domo股份有限公司是总部设在美国犹他州美国福克的美国云软件企业，主营人工智能、商业智能与数据可视化业务，属于SaaS（软件即服务）企业，核心产品可帮助企业各层级决策者在极少IT介入的情况下，实时获取业务数据，支撑决策开展。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
DOMO vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.6倍
$79.4M
营收增速更快
ZLAB
高出17.6%
-0.5%
自由现金流更多
DOMO
多$27.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-0.5%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $127.1M |
| 净利润 | $-10.4M | — |
| 毛利率 | 74.2% | 51.0% |
| 营业利润率 | -8.7% | -54.6% |
| 净利率 | -13.1% | — |
| 营收同比 | -0.5% | 17.1% |
| 净利润同比 | 44.6% | — |
| 每股收益（稀释后） | $-0.25 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMOZLAB
| Q4 25 | $79.4M | $127.1M | ||
| Q3 25 | $79.7M | $115.4M | ||
| Q2 25 | $80.1M | $109.1M | ||
| Q1 25 | $78.8M | $105.7M | ||
| Q4 24 | $79.8M | $108.5M | ||
| Q3 24 | $78.4M | $101.8M | ||
| Q2 24 | $80.1M | $100.1M | ||
| Q1 24 | $80.2M | $87.1M |
净利润DOMOZLAB
| Q4 25 | $-10.4M | — | ||
| Q3 25 | $-22.9M | $-36.0M | ||
| Q2 25 | $-18.1M | $-40.7M | ||
| Q1 25 | $-17.7M | $-48.4M | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-19.5M | $-41.7M | ||
| Q2 24 | $-26.0M | $-80.3M | ||
| Q1 24 | $-18.7M | $-53.5M |
毛利率DOMOZLAB
| Q4 25 | 74.2% | 51.0% | ||
| Q3 25 | 74.8% | 59.5% | ||
| Q2 25 | 74.2% | 60.6% | ||
| Q1 25 | 74.4% | 63.6% | ||
| Q4 24 | 75.0% | 61.5% | ||
| Q3 24 | 74.3% | 64.1% | ||
| Q2 24 | 74.1% | 64.9% | ||
| Q1 24 | 76.3% | 61.4% |
营业利润率DOMOZLAB
| Q4 25 | -8.7% | -54.6% | ||
| Q3 25 | -9.1% | -42.3% | ||
| Q2 25 | -17.9% | -50.3% | ||
| Q1 25 | -15.6% | -53.3% | ||
| Q4 24 | -13.9% | -62.6% | ||
| Q3 24 | -18.5% | -66.6% | ||
| Q2 24 | -26.8% | -76.0% | ||
| Q1 24 | -16.6% | -80.7% |
净利率DOMOZLAB
| Q4 25 | -13.1% | — | ||
| Q3 25 | -28.8% | -31.2% | ||
| Q2 25 | -22.5% | -37.3% | ||
| Q1 25 | -22.4% | -45.8% | ||
| Q4 24 | -23.5% | — | ||
| Q3 24 | -24.9% | -40.9% | ||
| Q2 24 | -32.5% | -80.2% | ||
| Q1 24 | -23.3% | -61.4% |
每股收益（稀释后）DOMOZLAB
| Q4 25 | $-0.25 | $-0.05 | ||
| Q3 25 | $-0.56 | $-0.03 | ||
| Q2 25 | $-0.45 | $-0.04 | ||
| Q1 25 | $-0.45 | $-0.04 | ||
| Q4 24 | $-0.48 | $-0.09 | ||
| Q3 24 | $-0.51 | $-0.04 | ||
| Q2 24 | $-0.69 | $-0.08 | ||
| Q1 24 | $-0.51 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $124.2M | — |
| 股东权益账面价值 | $-191.9M | $715.5M |
| 总资产 | $201.6M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOMOZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | $47.2M | $732.2M | ||
| Q1 25 | $45.3M | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | $61.2M | $630.0M | ||
| Q1 24 | $60.9M | $650.8M |
总债务DOMOZLAB
| Q4 25 | $124.2M | — | ||
| Q3 25 | $121.9M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $117.7M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $114.1M | — | ||
| Q1 24 | $113.5M | — |
股东权益DOMOZLAB
| Q4 25 | $-191.9M | $715.5M | ||
| Q3 25 | $-191.5M | $759.9M | ||
| Q2 25 | $-178.7M | $791.7M | ||
| Q1 25 | $-177.2M | $810.8M | ||
| Q4 24 | $-171.2M | $840.9M | ||
| Q3 24 | $-166.4M | $667.7M | ||
| Q2 24 | $-163.5M | $704.2M | ||
| Q1 24 | $-153.5M | $762.2M |
总资产DOMOZLAB
| Q4 25 | $201.6M | $1.2B | ||
| Q3 25 | $195.7M | $1.2B | ||
| Q2 25 | $189.7M | $1.2B | ||
| Q1 25 | $214.3M | $1.2B | ||
| Q4 24 | $190.2M | $1.2B | ||
| Q3 24 | $197.8M | $985.3M | ||
| Q2 24 | $204.4M | $987.4M | ||
| Q1 24 | $225.7M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $1.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 1.4% | -21.0% |
| 资本支出强度资本支出/营收 | 2.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $9.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流DOMOZLAB
| Q4 25 | $3.4M | $-26.0M | ||
| Q3 25 | $3.4M | $-32.0M | ||
| Q2 25 | $4.0M | $-31.0M | ||
| Q1 25 | $8.9M | $-61.7M | ||
| Q4 24 | $-13.7M | $-55.8M | ||
| Q3 24 | $-6.2M | $-26.8M | ||
| Q2 24 | $1.9M | $-42.2M | ||
| Q1 24 | $5.4M | $-90.1M |
自由现金流DOMOZLAB
| Q4 25 | $1.1M | $-26.7M | ||
| Q3 25 | $1.0M | $-35.0M | ||
| Q2 25 | $1.0M | $-33.9M | ||
| Q1 25 | $6.7M | $-63.2M | ||
| Q4 24 | $-16.2M | $-58.4M | ||
| Q3 24 | $-8.4M | $-28.2M | ||
| Q2 24 | $-625.0K | $-42.9M | ||
| Q1 24 | $2.9M | $-91.1M |
自由现金流率DOMOZLAB
| Q4 25 | 1.4% | -21.0% | ||
| Q3 25 | 1.3% | -30.4% | ||
| Q2 25 | 1.3% | -31.1% | ||
| Q1 25 | 8.5% | -59.9% | ||
| Q4 24 | -20.3% | -53.8% | ||
| Q3 24 | -10.7% | -27.7% | ||
| Q2 24 | -0.8% | -42.9% | ||
| Q1 24 | 3.6% | -104.5% |
资本支出强度DOMOZLAB
| Q4 25 | 2.9% | 0.5% | ||
| Q3 25 | 2.9% | 2.6% | ||
| Q2 25 | 3.7% | 2.6% | ||
| Q1 25 | 2.8% | 1.5% | ||
| Q4 24 | 3.2% | 2.4% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 3.2% | 0.7% | ||
| Q1 24 | 3.1% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
